Review





Similar Products

mmpi  (MedChemExpress)
94
MedChemExpress mmpi
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Mmpi, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/Marimastat/pmc12775852-186-21-24
Average 94 stars, based on 1 article reviews
mmpi - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
mmpi-iii  (Millipore)
90
Millipore mmpi-iii
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Mmpi Iii, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/mmpi+iii/pm39676862-78-20-21
Average 90 stars, based on 1 article reviews
mmpi-iii - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
broad spectrum matrix metalloproteinase inhibitor mmpi-iii  (Millipore)
90
Millipore broad spectrum matrix metalloproteinase inhibitor mmpi-iii
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Broad Spectrum Matrix Metalloproteinase Inhibitor Mmpi Iii, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/broad+spectrum+matrix+metalloproteinase+inhibitor+mmpi+iii/pm38697554-69-23-31
Average 90 stars, based on 1 article reviews
broad spectrum matrix metalloproteinase inhibitor mmpi-iii - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mmpi-3 rcd  (Credence Genomics)
90
Credence Genomics mmpi-3 rcd
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Mmpi 3 Rcd, supplied by Credence Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/mmpi+3+rcd/pm37249262-221-1-25
Average 90 stars, based on 1 article reviews
mmpi-3 rcd - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mmpi  (SRI Instruments)
90
SRI Instruments mmpi
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Mmpi, supplied by SRI Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/mmpi/pm35435018-187-14-17
Average 90 stars, based on 1 article reviews
mmpi - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
matrix metalloproteinase inhibitors (mmpis  (Schering-Plough corporation)
90
Schering-Plough corporation matrix metalloproteinase inhibitors (mmpis
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Matrix Metalloproteinase Inhibitors (Mmpis, supplied by Schering-Plough corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/matrix+metalloproteinase+inhibitors++mmpis/pm10504742-42-30-15
Average 90 stars, based on 1 article reviews
matrix metalloproteinase inhibitors (mmpis - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mmp-9 inhibitor ii mmpi  (Millipore)
90
Millipore mmp-9 inhibitor ii mmpi
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Mmp 9 Inhibitor Ii Mmpi, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/human+mmp+9/pm35490640-60-1-7
Average 90 stars, based on 1 article reviews
mmp-9 inhibitor ii mmpi - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mmpi-3 inefficacy (nfc) scales  (Onoda Cement Co Ltd)
90
Onoda Cement Co Ltd mmpi-3 inefficacy (nfc) scales
<t>W1</t> mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the <t>MMPi</t> (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.
Mmpi 3 Inefficacy (Nfc) Scales, supplied by Onoda Cement Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmpi%E2%80%93a/mmpi+3+inefficacy++nfc++scales/pm35175075-50-28-20
Average 90 stars, based on 1 article reviews
mmpi-3 inefficacy (nfc) scales - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


W1 mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the MMPi (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.

Journal: Molecular Therapy Oncology

Article Title: A monoclonal antibody W1 blocks mesothelin-mediated tumor progression

doi: 10.1016/j.omton.2025.201094

Figure Lengend Snippet: W1 mIgG1 inhibits ovarian cancer cell migration and invasion in a dose-dependent manner by downregulating MMP7 (A) Wound-healing assay showing the migration of OVCAR3 cells treated with increasing concentrations of W1 mIgG1 (100, 300, 600 nM). Data were normalized to the PBS group. (B) Transwell invasion assay demonstrating the dose-dependent suppression of OVCAR3 cell invasion by W1 mIgG1. RT-qPCR (C) and Western blot (D) analyses revealed that W1 mIgG1 treatment progressively reduced Mmp7 expression at both mRNA and protein levels in OVCAR3 cells, whereas A12H cIgG1 (300 nM) showed no effect. Comparative effects of W1 mIgG1 (300 nM) and the MMPi (1,000 nM) on MSLN-induced cell migration (E) and invasion (F). Both treatments showed similar inhibitory efficacy. All quantitative data are presented as mean ± SD from three biologically independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; data were analyzed by ANOVA followed by Tukey’s multiple comparison test.

Article Snippet: Therefore, a medium containing 2% FBS with MSLN-Fc, D1-Fc, D2-Fc, D3-Fc, Fc (100 nM), W1 mIgG1 or A12H cIgG1 (300 nM), MMPi (1,000 nM, MCE, cat#HY-12169), or PBS was added.

Techniques: Migration, Wound Healing Assay, Transwell Invasion Assay, Quantitative RT-PCR, Western Blot, Expressing, Comparison